BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61:967-969. [PMID: 22234982 DOI: 10.1136/gutjnl-2011-301348] [Cited by in Crossref: 126] [Cited by in F6Publishing: 103] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Bang UC, Benfield T, Hyldstrup L, Jensen JE, Bendtsen F. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. Liver Int. 2016;36:1304-1312. [PMID: 26992041 DOI: 10.1111/liv.13119] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
2 Téllez L, Ibáñez-Samaniego L, Pérez Del Villar C, Yotti R, Martínez J, Carrión L, Rodríguez de Santiago E, Rivera M, González-Mansilla A, Pastor Ó, Bermejo J, Bañares R, Albillos A. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol 2020;73:1404-14. [PMID: 32446716 DOI: 10.1016/j.jhep.2020.05.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
3 Reiberger T, Bucsics T, Paternostro R, Pfisterer N, Riedl F, Mandorfer M. Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them? Curr Hepatol Rep. 2018;17:301-315. [PMID: 30546995 DOI: 10.1007/s11901-018-0420-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Møller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int 2014;34:1153-63. [DOI: 10.1111/liv.12549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
5 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Mohta S, Shalimar, Saraya A. Long-term Outcomes with Carvedilol versus Propranolol in Patients with Index Variceal Bleed: 6-year Follow-up Study. J Clin Exp Hepatol 2021;11:343-53. [PMID: 33994717 DOI: 10.1016/j.jceh.2020.08.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Maiwall R, Pasupuleti SSR, Jain P, Sarin SK. Degree of Portal and Systemic Hemodynamic Alterations Predict Recurrent AKI and Chronic Kidney Disease in Patients With Cirrhosis. Hepatol Commun 2021;5:293-308. [PMID: 33553976 DOI: 10.1002/hep4.1607] [Reference Citation Analysis]
7 Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut. 2016;65:1393-1394. [PMID: 27207973 DOI: 10.1136/gutjnl-2016-312129] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
8 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
9 Shneider BL, de Ville de Goyet J, Leung DH, Srivastava A, Ling SC, Duché M, McKiernan P, Superina R, Squires RH, Bosch J, Groszmann R, Sarin SK, de Franchis R, Mazariegos GV. Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium. Hepatology 2016;63:1368-80. [PMID: 26358549 DOI: 10.1002/hep.28153] [Cited by in Crossref: 77] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
10 Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, Austin A, Ferguson JW, Olliff SP, Hudson M, Christie JM;  Clinical Services and Standards Committee of the British Society of Gastroenterology. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64:1680-1704. [PMID: 25887380 DOI: 10.1136/gutjnl-2015-309262] [Cited by in Crossref: 260] [Cited by in F6Publishing: 197] [Article Influence: 43.3] [Reference Citation Analysis]
11 Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38:407-414. [PMID: 23786291 DOI: 10.1111/apt.12382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
12 Kim BH, Chung JW, Lee CS, Jang ES, Jeong SH, Kim N, Kim JW. Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis. Korean J Intern Med 2019;34:1233-43. [PMID: 30759966 DOI: 10.3904/kjim.2018.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
13 Bossen L, Krag A, Vilstrup H, Watson H, Jepsen P. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients: Liver Failure/Cirrhosis/Portal Hypertension. Hepatology 2016;63:1968-76. [DOI: 10.1002/hep.28352] [Cited by in Crossref: 71] [Cited by in F6Publishing: 53] [Article Influence: 14.2] [Reference Citation Analysis]
14 Jepsen P, Tapper EB, Deleuran T, Kazankov K, Askgaard G, Sørensen HT, Vilstrup H, West J. Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study. Hepatology 2021. [PMID: 34137045 DOI: 10.1002/hep.32019] [Reference Citation Analysis]
15 Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018;38:570-80. [PMID: 28921803 DOI: 10.1111/liv.13589] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 19.0] [Reference Citation Analysis]
16 Muciño-Bermejo MJ. Mechanisms of kidney dysfunction in the cirrhotic patient: Non-hepatorenal acute-on-chronic kidney damage considerations. Ann Hepatol 2020;19:145-52. [PMID: 31594758 DOI: 10.1016/j.aohep.2019.06.022] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Li T, Ke W, Sun P, Chen X, Belgaumkar A, Huang Y, Xian W, Li J, Zheng Q. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6:e010902. [PMID: 27147389 DOI: 10.1136/bmjopen-2015-010902] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
18 Ferrarese A, Tikhonoff V, Casiglia E, Angeli P, Fasolato S, Faggian D, Zanetto A, Germani G, Russo FP, Burra P, Senzolo M. Hemodynamic Evaluation of Nonselective β-Blockers in Patients with Cirrhosis and Refractory Ascites. Gastroenterol Res Pract 2018;2018:4098210. [PMID: 29861720 DOI: 10.1155/2018/4098210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Snoga JL, Lusk KA, Attridge RT, Attridge RL. Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis. Ann Pharmacother 2020;54:322-30. [PMID: 31701773 DOI: 10.1177/1060028019886529] [Reference Citation Analysis]
20 Giannelli V, Roux O, Laouénan C, Manchon P, Ausloos F, Bachelet D, Rautou PE, Weiss E, Moreau R, Mebazaa A, Cohen-Solal A, Durand F, Francoz C. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol 2020;72:463-71. [PMID: 31622697 DOI: 10.1016/j.jhep.2019.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
21 Brito-Azevedo A, Perez Rde M, Coelho HS, Fernandes Ede S, Castiglione RC, Villela-Nogueira CA, Bouskela E. Propranolol improves endothelial dysfunction in advanced cirrhosis: The 'endothelial exhaustion' hypothesis. Gut. 2016;65:1391-1392. [PMID: 26984854 DOI: 10.1136/gutjnl-2016-311696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
22 Wong RJ, Robinson A, Ginzberg D, Gomes C, Liu B, Bhuket T. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis. Liver Int 2019;39:1080-8. [PMID: 30614656 DOI: 10.1111/liv.14040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
23 Kimer N, Wiese S, Mo S, Møller S, Bendtsen F. Advances in the treatment of portal hypertension in cirrhosis. Expert Rev Gastroenterol Hepatol 2016;10:961-9. [PMID: 26982499 DOI: 10.1586/17474124.2016.1166952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs 2016;21:167-81. [PMID: 27148904 DOI: 10.1080/14728214.2016.1184647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
25 Thiele M, Wiest R, Gluud LL, Albillos A, Krag A. Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? Med Hypotheses. 2013;81:871-874. [PMID: 24060485 DOI: 10.1016/j.mehy.2013.08.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
26 Facciorusso A, Roy S, Livadas S, Fevrier-paul A, Wekesa C, Kilic ID, Chaurasia AK, Sadeq M, Muscatiello N. Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites. Dig Dis Sci 2018;63:1737-46. [DOI: 10.1007/s10620-018-5092-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
27 Møller S, Bendtsen F. Complications of cirrhosis. A 50 years flashback. Scand J Gastroenterol. 2015;50:763-780. [PMID: 25881709 DOI: 10.3109/00365521.2015.1021709] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
28 Brito-Azevedo A. Diuretic window hypothesis in cirrhosis: Changing the point of view. World J Gastroenterol 2019; 25(26): 3283-3290 [PMID: 31341355 DOI: 10.3748/wjg.v25.i26.3283] [Reference Citation Analysis]
29 Krag A, Bendtsen F, Burroughs AK, Møller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses. 2012;79:53-55. [PMID: 22537409 DOI: 10.1016/j.mehy.2012.03.032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
30 Mattos AA, Wiltgen D, Jotz RF, Dornelles CMR, Fernandes MV, Mattos ÂZ. Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis. Ann Hepatol 2020;19:451-7. [PMID: 32533951 DOI: 10.1016/j.aohep.2020.04.010] [Reference Citation Analysis]
31 Garcia-Tsao G. Beta blockers in cirrhosis: The window re-opens. J Hepatol. 2016;64:532-534. [PMID: 26724557 DOI: 10.1016/j.jhep.2015.12.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
32 Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60:643-653. [PMID: 24076364 DOI: 10.1016/j.jhep.2013.09.016] [Cited by in Crossref: 83] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
33 Koshy AN, Farouque O, Cailes B, Ko J, Han HC, Weinberg L, Testro A, Robertson M, Teh AW, Lim HS, Gow PJ. Prediction of Perioperative Cardiovascular Events in Liver Transplantation. Transplantation 2021;105:593-601. [PMID: 32413014 DOI: 10.1097/TP.0000000000003306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
34 Yang J, Ge K, Chen L, Yang JL. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:1518-26. [PMID: 31094853 DOI: 10.1097/MEG.0000000000001442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
35 Ngwa T, Orman E, Gomez EV, Vuppalanchi R, Kubal C, Chalasani N, Ghabril M. Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation. BMC Gastroenterol 2020;20:4. [PMID: 31906860 DOI: 10.1186/s12876-019-1155-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
36 Ferrarese A, Zanetto A, Germani G, Burra P, Senzolo M. Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol 2016; 8(24): 1012-1018 [PMID: 27648153 DOI: 10.4254/wjh.v8.i24.1012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
37 Haq I, Tripathi D. Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf)5:113-126. [PMID: 28533909 DOI: 10.1093/gastro/gox007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
38 Tergast TL, Kimmann M, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B. Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. Aliment Pharmacol Ther. 2019;50:696-706. [PMID: 31373713 DOI: 10.1111/apt.15439] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
39 Kuo SZ, Lizaola B, Hayssen H, Lai JC. Beta-blockers and physical frailty in patients with end-stage liver disease. World J Gastroenterol 2018; 24(33): 3770-3775 [PMID: 30197482 DOI: 10.3748/wjg.v24.i33.3770] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Lin Y, Pan F, Wang Y, Chen Z, Lin C, Yao L, Zhang X, Zhou R, Pan C. Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases. Oncol Lett 2017;13:307-14. [PMID: 28123560 DOI: 10.3892/ol.2016.5393] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
41 Thorhauge KH, Lindvig KP, Laleman W, Angeli P, Singh SP, Krag A. Lack of consensus for usage of β-blockers in end-stage liver disease. Gut 2016;65:1058-60. [DOI: 10.1136/gutjnl-2016-311573] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
42 Rajoriya N, Tripathi D. Non-selective beta-blockers in cirrhosis: Current concepts and controversies. World J Pharmacol 2016; 5(1): 15-31 [DOI: 10.5497/wjp.v5.i1.15] [Reference Citation Analysis]
43 Kimer N, Feineis M, Møller S, Bendtsen F. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol. 2015;50:129-137. [PMID: 25113796 DOI: 10.3109/00365521.2014.948053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
44 Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746 [PMID: 34367495 DOI: 10.4254/wjh.v13.i7.731] [Reference Citation Analysis]
45 Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J Gastroenterol 2018; 24(38): 4356-4368 [PMID: 30344420 DOI: 10.3748/wjg.v24.i38.4356] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
46 Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017;67:40-46. [PMID: 28213164 DOI: 10.1016/j.jhep.2017.02.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
47 Leithead JA, Rajoriya N, Tehami N, Hodson J, Gunson BK, Tripathi D, Ferguson JW. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015;64:1111-9. [DOI: 10.1136/gutjnl-2013-306502] [Cited by in Crossref: 112] [Cited by in F6Publishing: 82] [Article Influence: 16.0] [Reference Citation Analysis]
48 Vespasiani-Gentilucci U, Rombouts K. Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension. Gut 2015;64:523-4. [PMID: 24966286 DOI: 10.1136/gutjnl-2014-307583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
49 Thiele M, Krag A, Rohde U, Gluud LL. Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther. 2012;35:1155-1165. [PMID: 22449261 DOI: 10.1111/j.1365-2036.2012.05074.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
50 Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep. 2014;6:95. [PMID: 25374673 DOI: 10.12703/P6-95] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
51 Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, Riggio O, Venditti M. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35:362-369. [PMID: 24836902 DOI: 10.1111/liv.12593] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
52 Ge PS, Runyon BA. Beta-blockers in cirrhosis: Thank you for your attention. Journal of Hepatology 2014;61:451-2. [DOI: 10.1016/j.jhep.2014.04.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
53 Harding DJ, Perera MTP, Chen F, Olliff S, Tripathi D. Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol 2015; 21(22): 6769-6784 [PMID: 26078553 DOI: 10.3748/wjg.v21.i22.6769] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
54 Madsen BS, Havelund T, Krag A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv Ther 2013;30:659-70. [PMID: 23881723 DOI: 10.1007/s12325-013-0044-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
55 Facciorusso A. Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.Ther Clin Risk Manag. 2019;15:1383-1391. [PMID: 31819465 DOI: 10.2147/TCRM.S205328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49:3-10. [PMID: 27717792 DOI: 10.1016/j.dld.2016.09.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
57 Bajaj JS, O'Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut. 2012;61:1219-1225. [PMID: 22661495 DOI: 10.1136/gutjnl-2012-302339] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
58 Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018;10:55-71. [PMID: 30013405 DOI: 10.2147/hmer.s136578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
59 Shukla R, Kramer J, Cao Y, Ying J, Tansel A, Walder A, Advani S, El-serag HB, Kanwal F. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. American Journal of Gastroenterology 2016;111:1778-87. [DOI: 10.1038/ajg.2016.440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
60 Onali S, Kalafateli M, Majumdar A, Westbrook R, O'Beirne J, Leandro G, Patch D, Tsochatzis EA. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver Int. 2017;37:1334-1344. [PMID: 28296047 DOI: 10.1111/liv.13409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
61 Lee SK, Song MJ, Kim SH, Ahn HJ. Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis. Clin Mol Hepatol. 2018;24:409-416. [PMID: 30145855 DOI: 10.3350/cmh.2018.0034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
62 Krag A, Madsen BS. To block, or not to block in advanced cirrhosis and ascites: that is the question. Gut 2015;64:1015-7. [PMID: 25398769 DOI: 10.1136/gutjnl-2014-308424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
63 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 D'Amico G, Malizia G, Bosch J. Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension? Hepatology 2016;63:1771-3. [PMID: 26890689 DOI: 10.1002/hep.28502] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
65 Pfisterer N, Dexheimer C, Fuchs EM, Bucsics T, Schwabl P, Mandorfer M, Gessl I, Sandrieser L, Baumann L, Riedl F, Scheiner B, Pachofszky T, Dolak W, Schrutka-Kölbl C, Ferlitsch A, Schöniger-Hekele M, Peck-Radosavljevic M, Trauner M, Madl C, Reiberger T. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther 2018;47:966-79. [PMID: 29388229 DOI: 10.1111/apt.14485] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
66 Thevenot T, Mouhat B, Cervoni J, Chopard R. The dual role of non‐selective beta‐blockers in cirrhotic patients: How do we know when Dr Jekyll turns into Mr Hyde? Liver Int 2021;41:1166-7. [DOI: 10.1111/liv.14770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol 2020;73:829-41. [PMID: 32298768 DOI: 10.1016/j.jhep.2020.03.048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
68 Kalambokis GN, Baltayiannis G, Christou L, Christodoulou D. Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use. Gut 2016;65:1228-30. [PMID: 26935875 DOI: 10.1136/gutjnl-2016-311527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
69 Mura VL, Tosetti G, Primignani M, Salerno F. Use of non-selective beta blockers in cirrhosis: The evidence we need before closing (or not) the window. World J Gastroenterol 2015; 21(8): 2265-2268 [PMID: 25741132 DOI: 10.3748/wjg.v21.i8.2265] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
70 Lenz K, Buder R, Kapun L, Voglmayr M. Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol 2015;8:83-100. [PMID: 25729433 DOI: 10.1177/1756283X14564673] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
71 Garcia Garcia de Paredes A, Manicardi N, Tellez L, Ibañez L, Royo F, Bermejo J, Blanco C, Fondevila C, Fernandez Lanza V, Garcia-Bermejo L, Falcon-Perez JM, Bañares R, Gracia-Sancho J, Albillos A. Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. Hepatol Commun 2021;5:309-22. [PMID: 33553977 DOI: 10.1002/hep4.1642] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
72 Kang SH, Lee M, Kim MY, Lee JH, Jun BG, Kim TS, Choi DH, Suk KT, Kim YD, Cheon GJ, Kim DJ, Baik SK. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatol Int 2021;15:424-36. [PMID: 33860898 DOI: 10.1007/s12072-021-10160-3] [Reference Citation Analysis]
73 Dever JB, Sheikh MY. Editorial: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention. Authors' reply. Aliment Pharmacol Ther 2015;41:1298. [PMID: 25968149 DOI: 10.1111/apt.13226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
74 Pfisterer N, Schmidbauer C, Riedl F, Maieron A, Stadlbauer V, Hennlich B, Schwarzer R, Puespoek A, Bucsics T, Effenberger M, Bota S, Gschwantler M, Peck-Radosavljevic M, Mandorfer M, Madl C, Trauner M, Reiberger T. Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. Wien Klin Wochenschr. 2021;133:421-431. [PMID: 33270161 DOI: 10.1007/s00508-020-01769-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
76 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
77 Lenz K, Binder M, Buder R, Gruber A, Gutschreiter B, Voglmayr M. Niereninsuffizienz bei Patienten mit Leberinsuffizienz. Med Klin Intensivmed Notfmed 2014;109:240-5. [DOI: 10.1007/s00063-013-0322-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Sharma S. Thromboelastometry in patients with advanced chronic liver disease: a complex interplay. Hepatol Int 2021;15:520-1. [PMID: 33512645 DOI: 10.1007/s12072-021-10142-5] [Reference Citation Analysis]
79 Ferrarese A, Tsochatzis E, Burroughs AK, Senzolo M. Beta-blockers in cirrhosis: therapeutic window or an aspirin for all? J Hepatol. 2014;61:449-450. [PMID: 24768827 DOI: 10.1016/j.jhep.2014.03.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
80 Koshy AN, Farouque O, Cailes B, Testro A, Ramchand J, Sajeev JK, Han HC, Srivastava PM, Jones EF, Salehi H, Teh AW, Lim HS, Calafiore P, Gow PJ. Impaired Cardiac Reserve on Dobutamine Stress Echocardiography Predicts the Development of Hepatorenal Syndrome. Am J Gastroenterol 2020;115:388-97. [PMID: 31738284 DOI: 10.14309/ajg.0000000000000462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
81 Albillos A, Tejedor M. Secondary prophylaxis for esophageal variceal bleeding. Clin Liver Dis 2014;18:359-70. [PMID: 24679500 DOI: 10.1016/j.cld.2014.01.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
82 Stundiene I, Sarnelyte J, Norkute A, Aidietiene S, Liakina V, Masalaite L, Valantinas J. Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review. World J Gastroenterol 2019; 25(32): 4779-4795 [PMID: 31528101 DOI: 10.3748/wjg.v25.i32.4779] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
83 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 10] [Article Influence: 10.5] [Reference Citation Analysis]
84 Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, Blacky A, Ferlitsch A, Sieghart W. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680-1690.e1. [PMID: 24631577 DOI: 10.1053/j.gastro.2014.03.005] [Cited by in Crossref: 245] [Cited by in F6Publishing: 179] [Article Influence: 35.0] [Reference Citation Analysis]
85 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
86 Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med 2020;8:220-36. [PMID: 33511049 DOI: 10.2478/jtim-2020-0035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Ge PS, Runyon BA. When Should the β-Blocker Window in Cirrhosis Close? Gastroenterology 2014;146:1597-9. [DOI: 10.1053/j.gastro.2014.04.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
88 Kirnake V, Arora A, Gupta V, Sharma P, Singla V, Bansal N, Goyal M, Chawlani R, Kumar A. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study. J Clin Exp Hepatol 2016;6:175-85. [PMID: 27746613 DOI: 10.1016/j.jceh.2016.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
89 Koay EJ, Owen D, Das P. Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 2018;28:321-31. [PMID: 30309642 DOI: 10.1016/j.semradonc.2018.06.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
90 Blasco-Algora S, Masegosa-Ataz J, Alonso S, Gutiérrez ML, Fernández-Rodriguez C. Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol 2016;3:e000104. [PMID: 28074149 DOI: 10.1136/bmjgast-2016-000104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
91 Noh MR, Jang HS, Kim J, Padanilam BJ. Renal Sympathetic Nerve-Derived Signaling in Acute and Chronic kidney Diseases. Int J Mol Sci 2020;21:E1647. [PMID: 32121260 DOI: 10.3390/ijms21051647] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
92 Sersté T, Njimi H, Degré D, Deltenre P, Schreiber J, Lepida A, Trépo E, Gustot T, Moreno C. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis. Liver Int. 2015;35:1974-1982. [PMID: 25611961 DOI: 10.1111/liv.12786] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
93 Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H; Vienna Hepatic Hemodynamic Lab. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58:911-921. [PMID: 23262249 DOI: 10.1016/j.jhep.2012.12.011] [Cited by in Crossref: 184] [Cited by in F6Publishing: 160] [Article Influence: 20.4] [Reference Citation Analysis]
94 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460. [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024] [Cited by in Crossref: 660] [Cited by in F6Publishing: 522] [Article Influence: 220.0] [Reference Citation Analysis]
95 Gillespie S, Hayes PC. Editorial: when to start carvedilol in cirrhosis—time to reconsider? Aliment Pharmacol Ther 2021;54:726-7. [DOI: 10.1111/apt.16512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
97 Facciorusso A, Antonino M, Orsitto E, Sacco R. Primary and secondary prophylaxis of spontaneous bacterial peritonitis: current state of the art. Expert Rev Gastroenterol Hepatol 2019;13:751-9. [PMID: 31304804 DOI: 10.1080/17474124.2019.1644167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Role of band ligation for secondary prophylaxis of variceal bleeding. World J Gastroenterol 2018; 24(26): 2902-2914 [PMID: 30018485 DOI: 10.3748/wjg.v24.i26.2902] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Stanley AJ, Dickson S, Hayes PC, Forrest EH, Mills PR, Tripathi D, Leithead JA, MacBeth K, Smith L, Gaya DR, Suzuki H, Young D. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol. 2014;61:1014-1019. [PMID: 24953021 DOI: 10.1016/j.jhep.2014.06.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
100 Yotti R, Ripoll C, Benito Y, Catalina MV, Elízaga J, Rincón D, Fernández-avilés F, Bermejo J, Bañares R. Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. Hepatology 2017;65:2019-30. [DOI: 10.1002/hep.29104] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
101 Lee PC, Chen YJ, Chou YC, Lee KC, Chen PH, Kao WY, Huang YH, Huo TI, Lin HC, Hou MC, Lee FY, Wu JC, Su CW. Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2020;32:365-72. [PMID: 31688303 DOI: 10.1097/MEG.0000000000001511] [Reference Citation Analysis]
102 Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S, Neagu M, Rössle M, Zipprich A, Caca K, Ferlitsch A, Dilger K, Mohrbacher R, Greinwald R, Sauerbruch T. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis 2015;47:144-50. [PMID: 25483910 DOI: 10.1016/j.dld.2014.10.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
103 Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017;66:849-859. [PMID: 27864004 DOI: 10.1016/j.jhep.2016.11.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 14.8] [Reference Citation Analysis]